SIGLEC5

Across TCGA pan-cancer cohorts, SIGLEC5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIGLEC5 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SIGLEC5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SIGLEC5 expression acts as an unfavorable survival marker.

DLBC, ESCA, and PCPG are the cancer types where SIGLEC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
ESCA	OS	Median	All	0.198	0.872	.003	12	view →
PCPG	DFS	Median	All	0.086	0.768	<.001	6	view →
LUAD	OS	Median	All	0.238	0.697	.015	6	view →
SKCM	OS	Median	III,IV	0.371	0.742	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIGLEC5–DLBC (OS)

Open the DLBC breakdown →